6th Tropé - Kolstad meeting

UPDATES IN GYNECOLOGIC ONCOLOGY

Friday December 4. 2015
Auditorium, Institute for Cancer Research
The Norwegian Radium Hospital, Oslo, Norway

Sponsored by
INGER AND JOHN FREDRIKSEN FOUNDATION FOR OVARIAN CANCER RESEARCH
The last years we have had a striking development within the field of gynecologic oncology with both big and small improvements. Chemo resistance-associated molecules in primary and metastatic epithelial ovarian cancer, molecular profiling of metastatic epithelial ovarian cancer, targeting treatment based on prediction tests on molecular marks of the tumor have come to stay. Checkpoint immune therapy and its potential role in ovarian cancer has increased.

The agenda for this meeting is the genomic categorization of endometrial carcinoma and clinical implementation of molecular and imaging biomarkers. The state of the art treatment of ovarian germ cell tumors and surgery of advanced epithelial ovarian cancer will also be discussed. These themes will be discussed by renown experts in the field from around the world. We are very proud that they have accepted our invitation.

Welcome to this exciting meeting, we hope that the meeting will be both interesting and informative.

Oslo, 4th of December 2015

Claes Tropé
Chair
Inger and John Fredriksen foundation for ovarian cancer research
## SCIENTIFIC PROGRAM - DECEMBER 4, 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:00 - 09:05 | Welcome<br>
               Dr. Erik Rokkones, MD, PhD, Chairman of the Gynecological Oncology, The Norwegian Radium Hospital |
| 09:05 - 09:35 | Molecular Characteristics of Gynecological Cancer<br>
               Chair: Dr. Janne Kærn, MD, PhD (Norway) & Dr. Anne Dørum, MD, PhD (Norway) |
| 09:05 - 09:35 | Gynecologic Cancer Cell Research, Then and Now<br>
               Prof. Nelly Auersperg, MD, PhD (Canada) |
| 09:35 - 09:40 | Discussion |
| 09:40 - 10:00 | Chemoresistance-Associated Molecules in Primary and Metastatic Ovarian Carcinoma<br>
               PhD, student, Dag. Nymoen (Norway) |
| 10:00 - 10:35 | Genomic Categorization of Endometrial Carcinoma: Implications for Diagnosis, Treatment and Prognostication<br>
               Prof. Robert A. Soslow, MD (USA) |
| 10:35 - 10:40 | Discussion |
| 10:40 - 11:00 | Coffee Break |
| 11:00 - 11:25 | Clinical Implementation of Molecular and Imaging Biomarkers, Potential and Challenges for Improving Endometrial Carcinoma Patient Care<br>
               Prof. Helga Salvesen, MD, PhD (Norway) |
| 11:25 - 11:30 | Discussion |
| 11:30 - 11:50 | Impact of Morcellation on Survival of Patients with Unexpected Uterine Leiomyosarcoma: A systematic Review and Meta-analysis<br>
               Prof. Giovanni Aletti, MD (Italy) |
| 11:50 - 12:00 | Impact of Morcellation on Survival of Patients with Unexpected Uterine Leiomyosarcoma: The Norwegian Experience<br>
               Dr. Bjørn Busund MD, (Norway) |
| 12:00 - 12:55 | Molecular Profiling of Metastatic Ovarian Carcinoma<br>
               Prof. Ben Davidson, MD, PhD (Norway) |
| 13:00 - 13:55 | Lunch |
## CONTROVERSIES IN OVARIAN CANCER TREATMENT
*Chair: Dr. Bilal Sert, MD (Norway)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:20</td>
<td>Primary or Internal Debulking? The Case after Five Randomized Trials</td>
<td>Prof. Amin Makar, MD, PhD (Belgium)</td>
<td>Belgium</td>
</tr>
<tr>
<td>14:20 - 14:25</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## IMMUNOTHERAPY IN OVARIAN CANCER
*Chair: Dr. Rita Steen, MD, PhD (Norway)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:25 - 14:45</td>
<td>Checkpoint Immunotherapies and Their Potential Role in Cancer</td>
<td>Dr. Olesya Solheim, MD, PhD (Norway)</td>
<td>Norway</td>
</tr>
<tr>
<td>14:45 - 14:50</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:50 - 15:20</td>
<td>Immunotherapy Hype or Hope?</td>
<td>Prof. Christian Marth, MD, PhD (Austria)</td>
<td></td>
</tr>
<tr>
<td>15:20 - 15:25</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:25 - 16:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## GERM CELL TUMORS OF THE OVARY
*Chair: Prof. Bjørn Hagen, MD, PhD (Norway)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:30</td>
<td>State of the Art Treatment of Ovarian Germ Cell Tumors</td>
<td>Prof. Michael Seckl, MD, PhD (UK)</td>
<td>UK</td>
</tr>
<tr>
<td>16:30 - 16:35</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## CERVICAL CANCER: HISTORY OF COLPOSCOPY
*Chair: Dr. Ameli Tropé, MD, PhD (Norway) & Prof. Gunnar Kristensen, MD, PhD (Norway)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:35 - 17:05</td>
<td>Fifty Years traveling Through Colposcopy</td>
<td>Prof. Alfred Singer, MD, PhD (UK)</td>
<td>UK</td>
</tr>
<tr>
<td>17:05 - 17:10</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:10 - 17:40</td>
<td>An Unfortunate Experiment</td>
<td>Prof. Joseph Jordan, MD, PhD (UK)</td>
<td>UK</td>
</tr>
<tr>
<td>17:40 - 17:50</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:50 - 18:00</td>
<td>Closing Remarks</td>
<td>Prof. Michael Seckl, MD, PhD (UK)</td>
<td></td>
</tr>
</tbody>
</table>
Prof. Nelly Auersperg, M.D., Ph.D. has focused her career on advancing the understanding of cervical and ovarian carcinogenesis, using cell biological and tissue culture methodologies. Her first line of research, at the B.C. Cancer Institute and University of British Columbia in Vancouver, B. C. Canada, was to establish a research program aimed at the development of in vitro approaches to investigate growth and differentiation of cancers of the cervix.

This work resulted in improved culture methods, information on early cytogenetic changes, definition of microenvironmental influences, and the development of the first human cervical cancer lines with defined differentiation, which contributed to the discovery of HPV as the cause of cervical cancer.

In 1974, her interest shifted to ovarian cancers, and in particular the question of their origin. At that time, few others were studying the biological basis of this disease. This dearth of research meant that she needed to develop many of the tools used for her studies herself, leading to discoveries that have increased our understanding of the disease. Throughout her career, Professor Auersperg has been a prolific researcher and author, with over 200 refereed journal articles and more than 11 book chapters to her name. She has also been a dedicated teacher, mentoring more than 60 graduate and post-graduate students over the years. Many of those who benefited from her tutelage have forged successful research careers of their own.

Among many other distinctions, she was named a Terry Fox Research Scientist (the highest distinction for cancer researchers in Canada), received an honorary Doctor of Science degree from Simon Fraser University (Burnaby, B.C., Canada), and was made a Fellow of the Royal Society of Medicine (UK). She is also the recipient of a Lifetime Achievement Award from the Society for In Vitro Biology (USA).

Professor Auersperg’s work continued long after her official retirement. In fact, she held research grants and carried out experiments for another 15 years, and published her most recent articles in 2013. She remains a Professor Emerita of Obstetrics and Gynecology at the University of British Columbia. Her current interests center on early detection markers and relationships between tubal and ovarian carcinogenesis.
Name: Dag Andre Nymoen
Date and place of birth: Mars 26, 1971; Lørenskog, Norway
Citizenship: Norwegian
Education:
1993-1997: Engineer in Biotechnology, Hedmark College
1997-2002: Master in Biotechnology, Oslo University
Brief Chronology of employment:
2002-2013: Engineer at Molecular Pathology Laboratory.
2013-        : Engineer at Molecular Pathology Laboratory (50%) and Phd student (50%)
Membership in professional and scientific societies
2014- : Steering committee member Nordic Molecular Hematology Lab Group (NMHLG)
2006- : Lecture in QPCR technology, Oslo College
Publications (excluding abstracts) in peer-reviewed journals: 22 per November 2015 in New York.
Dr. Robert Soslow MD.
Director of Translational and Clinical Research in the Dep. Of Pathology at Memorial Sloan Kettering Cancer Center, New York City

Dr. Robert Soslow is the Director of Gynecologic Pathology and the Gynecologic Pathology fellowship program and the Director of Translational and Clinical Research in the Department of Pathology at Memorial Sloan Kettering Cancer Center in New York City.

After his Bachelor of Arts degree in Modern Near Eastern Studies, Dr. Soslow completed medical school at the University of Pennsylvania. He completed residency in Anatomic Pathology and fellowships in Surgical Pathology and Immunopathology at Stanford University Medical Center.

In 2006, he was named Professor of Pathology and Laboratory Medicine at the Weill Medical College of Cornell University and Full Member at Memorial Sloan Kettering Cancer Center. With over 250 peer-reviewed publications, he is one of the foremost authorities on gynecologic malignancies. His recent research interests include hereditary gynecologic cancer syndromes and genotype-phenotype correlations in endometrial and ovarian carcinomas. He heads the gynecologic pathology team at Memorial Hospital, which now includes outstanding individuals with expertise in cervical and vulvar carcinomas, uterine sarcoma, gestational trophoblastic disease, molecular pathology and translational research. He is an award-winning teacher and mentor to junior attending staff and aspiring fellows. He has authored three textbooks and twenty book chapters on gynecologic pathology and is currently preparing two AFIP Fascicles for the Fourth Series of the AFIP’s Tumor Atlases. He has also lectured in twenty-four countries.

Given his accomplishments, it is not surprising that, from 2011 to 2015, Dr. Soslow was named in New York Magazine's Top Doctors in New York, and in the US News and World Report's America's Top Doctors. On a more personal note, Dr. Soslow is married to his partner of 29 years, Michael, and enjoys traveling, reading, photography, collecting banknotes, learning foreign languages, figure skating, weight training and pilates.

Educational Background

1982-1986 1986 University of Pennsylvania, B.A.

Academic positions

2015- Director of Clinical and Translational Research, Department of Pathology, Memorial Hospital for Cancer and Allied Diseases

Hospital positions

2010- Director of Gynecologic Pathology, Department of Pathology, Memorial Hospital for Cancer and Allied Diseases

Professional Memberships

United States and Canadian Academy of Pathology
International Society of Gynecological Pathologists
Gynecologic Oncology Group

Honors and awards

MSKCC Department of Pathology Teaching Award

Bibliography 254
Book Chapters 20

Invited lectures and presentations in more than 24 countries
Place and Date of birth: Milano, Italy on October 30, 1973. Citizenship: Italian
Work address: European Institute of Oncology, Via Ripamonti, 435, 20141. Milano
Ph 0294372069
E-mail: giovanni.aletti@ieo.it
Current Position: Deputy Director, Division of Gynaecology. European Institute of Oncology, Milano, Italy
EDUCATION
1987-1992 High School
1992-1998 Medical School, University of Milano, Italy.
Thesis: “Role of Urokinase Receptor (u-PAR) in Ovarian Cancer” (Summa cum laude)
Clinical Activity
1995-1996 Department of Internal Medicine “L.Sacco”, Policlinico Hospital University of Milano
1996 Department of General Surgery “Monteggia”, Policlinico Hospital University of Milano
1996-1998 Department of Gynecology and Obstetrics, S. Raffaele Hospital University of Milano
Residency
1999-2004 Residency in Gynecology and Obstetrics at S. Raffaele Hospital (Milano).
Subspecialty Fellowship (Gynecologic Oncology 6/2006-6/2009 – Fellowship in Gynecologic Oncology at Mayo Clinic, Rochester, MN. (Program Director: Dr. William Cliby)
Research Fellowship
12/2005-6/200 Research fellowship (mentor Dr. William Cliby) – Mayo Clinic, Rochester, MN
Research and clinical interests
Gynecologic Oncology Surgery
Prognostic factors in Gynecologic Cancer
Chemosensitivity and ovarian cancer
Genetics of Gynecologic Cancer (Ovarian Cancer)
Pelvic Floor and Urologic Surgery
International Presentations 67
Peer Reviewed Articles 65
Professor Ben Davidson, MD, PhD
Oslo University Hospital, the Norwegian Radium Hospital, Oslo, Norway

Date and place of birth: September 23, 1964; Tel Aviv, Israel. Citizenship: Israeli

Present position: Senior Pathologist and Head of Research, Department of Pathology, Oslo University Hospital; Professor, University of Oslo

Education
2003-2004: Post-doctoral fellow at NCI/NIH, Bethesda MD
1998-2001: Ph.D. program, Norwegian Radium Hospital; Thesis defended 23/8/01
1986-1992: Medical studies in Sackler School of Medicine, Tel-Aviv University

Brief Chronology of employment
2002-present: Staff pathologist, Department of Pathology, Norwegian Radium Hospital, Oslo, Norway; Sub-specialist in cytopathology and gynecologic pathology
1998-2002: Resident (combined with PhD program), Department of Pathology, Norwegian Radium Hospital, Oslo, Norway
1994-1998: Resident, Department of Pathology, Sheba Medical Center, Tel Hashomer, Israel

Membership in professional and scientific societies
1. The American Association for Cancer Research; 2. The International Academy of Pathology (Norwegian division); 3. The European Society of Pathology; 4. The International Society of Gynecological Pathology; 5. Nordic Society of Gynecologic Oncology

Scientific appointments
2012-: Editorial board member in Gynecologic Oncology
2011-: Associate Editor, Frontiers in Women’s Cancer
2011-: Editorial board member in Human Pathology
2010-: Editorial board member in Virchows Archiv
2010-: Associate Editor, Journal of Oncology, Special issue titled Molecular Genetic Markers in Female Reproductive Cancers
2006-2013: Member of the grant application committee, Norwegian Cancer Society
2005-2012: Section Editor in Diagnostic Cytopathology

Invited speaker and Reviewer
- Invited speaker in 26 sessions in international conferences in 2004-2014

Publications (excluding abstracts) in peer-reviewed journals: 257 per November 2014
In addition, Editor of a book on serous effusions with Springer and author of 5 chapters.
Professor Dr. Amin Philip MAKAR, MD, PhD.
Date of Birth: 060659 - Egypt
Training in Gynecology and Gynecologic Oncology:
1989 - 1992: Training in Gynecologic Oncology at The Norwegian RadiumHospital, Oslo, Norway under supervision of Professor Dr Claes Tropé MD, Ph.D.
1993 Doctoral thesis on the topic "Ovarian and tubal malignancies. Prognostic studies with emphasis on serum CA 125 and c-erbB-2 oncogene". University of Oslo,
Present position:
Gynecologic Oncologist and director of the breast Unite of the Middelheim Hospital, Antwerpen, Belgium
Professor Gynecologic Oncology at the department of Gynecology, University of Ghent, Belgium.
Trainee supervisor.
Membership International organisations:
ISGC: International Society of Gynecologic Cancer
EORTC: Gynecology group
Flemish work group for Gynecologic Oncology
Scientific prize:
2000: "Golden Hippocrates 2000 prize" awarded by the Belgian doctor’s magazine “Artsenkrant”.
2001 Reasons for selections as stated by the magazine have been: “high scientific quality and strong human commitment to oncology patients”. The award was personally presented by Minister of social affairs Fr. Van den Broucke
Promotor of doctoral thesis:
1. Epidemiologische en economische impact van HPV vaccinatie. Sarah Jurissen (6/08)
2. Incidentie van micrometastasen bij gynaecologische tumoren.
Impact op prognose en therapeutische beslissingen. Stéphanie Delens (6/08)
New insights in staging and treatment of advanced cervical cancer.
PhD. Dr Philippe tummers, University of Ghent. 050914.
Peer Reviewed Articles in Oncology 91
Presentations and posters in Oncology 203
Dr. Olesya Solheim, MD, PhD fellow
Oslo University Hospital, the Norwegian Radium Hospital, Oslo, Norway

Dr. Olesya Solheim has her medical education from the State Medical Academy of Arkhangelsk, Russia, 1999. After receiving her degree as medical doctor she underwent 4 years of specialization within obstetrics and gynecology from the same institution.

Dr Solheim moved to Norway in 2003 and received authorization of her medical education from Russia as professionally equivalent to the degree Candidate of Medicine of the University of Oslo (Candidatea Medicinae - Cand. Med.). Having settled in Oslo she has been working at different departments of Oslo University hospital. In the period 2006-2007, she was trained in internal medicine at Lillehammer hospital, and was in 2007 authorized as medical doctor by the Norwegian governmental office for authorization of health personnel.

Since 2008 she has been working at the Oslo University Hospital, Dep. Of Gynecological Oncology, the Norwegian Radium Hospital.
From March 2012 Olesya Solheim has been engaged as PhD fellow in the project "Long-term outcome in survivors after Germ Cell Ovarian Cancer". This project is the first national study of Germ Cell ovarian tumors and is conducted in cooperation between the Departments of gynecological oncology in Oslo, Trondheim, Bergen, Tromsø and the National Resource Center for Studies after Treatment for Cancer OUS, the Norwegian Radium Hospital.

Publications:


Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"

The Impact of Cisplatinum-Based Chemotherapy on Ventricular Function and Cardiovascular Risk Factors in Female Survivors after Malignant Germ Cell Cancer
Klaus Murbraech, Olesya Solheim, Hanne M Aulie, Sophie D Fossaa, Svend Aakhus.
ESC Heart Failure; 2015DOI: 10.1002/ehf2.12048.
Prof. Christian Marth MD, PhD
Director of Department of Obstetrics and Gynecology, Innsbruck, Austria

Prof. Christian Marth, MD, PhD, is the Director of the Department of Obstetrics & Gynecology Innsbruck Austria.

Christian Marth received his medical degree from the Leopold Franzens University of Innsbruck, Faculty of Medicine, in 1985, performed his residency in gynecology & obstetrics from 1985-1991, registered as a fellow in obstetrics and gynecology in 1991, and completed his habilitation and was awarded venia legendi in gynecology and obstetrics with the thesis “Biological modulators in ovarian cancer” from the University Innsbruck in 1991.

1996 – 1998 Christian Marth was senior physician at Det Norske Radiumhospital in Oslo (Norway). Since October 1998 he is the director of the Department of Obstetrics and Gynecology at the University Hospital Innsbruck.

Christian Marth is a member of many medical societies, including the European Society of Gynecologic Oncology (ESGO), the International Society of Gynecologic Cancer (IGCS), the American Society of Clinical Oncology (ASCO), the Austrian Society of Gynecology and Obstetrics (OEGGG).

He is an executive board member of the Gynecologic Cancer Intergroup (GCIG). Actually he is the president of the ENGOT and of the Austrian Association for Gynecologic Oncology (AGO), vice president of the ABCSG (Austrian Breast and Colorectal Cancer Study Group).

Christian Marth has been the author or co-author of more than 360 scientific articles, reviews, and book chapters. He received 13 national and international awards.
Prof. Michael Seckl, MD, PhD
Director of Postgraduate Studies of the dep. Of Surgery and Cancer

Michael Seckl trained at University College London obtaining a BSc in Immunology in 1983 and his MBBS in 1986.

He did his general professional and specialist medical oncology training on the London circuit becoming initially a member and then a fellow of the Royal College of Physicians.

He obtained his PhD in biochemistry in 1995 from the London Research Institute/University College London and was that year appointed as a Senior Lecturer/honorary consultant in medical oncology at Charing Cross Hospital which subsequently became part of Imperial College London.

He then established his own research groups working on cell signalling in cancer and trophoblastic disease supported by grants from Cancer Research UK, the Medical Research Council, Wellcome Trust, Wellbeing, Industry and others.

He was promoted to Reader in 2002 and the Professor of Molecular Oncology in 2004 when he also took on the directorship of the Charing Cross Gestational Trophoblastic Disease Centre and the supraregional Tumour Marker Assay Service. In 2007 he initiated a process to develop a new national service for Malignant Ovarian Germ Cell Tumours and in 2012 became head of this service.

Professor Seckl also leads the Imperial College Experimental Cancer Medicine Centre, runs the London Lung Cancer Alliance, is on the editorial board of several journals, chairs and sits on several grants committees, is the president elect of the European Organisation for the Treatment of Trophoblastic Disease, treasurer of the International Society for the Study of Trophoblastic Disease and holds an honorary professorship with the Peking Union Medical College.

Educationally, he is Director of Postgraduate Studies for the department of Surgery and Cancer with overall responsibility for 200 MSc/MRes and 400 PhD students. Within his own research group, he and his team have received several international prizes for their work and in the past 5 years have raised over £18M of grant income. He remains committed to teaching, research and his patients.
Clinical & Research Activities
Specialist interest in gynaecological oncology especially in relation to the cervix, established a large clinical & research unit in colposcopy and lower genital tract pre-cancer. This unit has been attached to University College London since 1983 with 47 research fellows and associates working in clinical and research based studies in both units.
Major research interests have included studies into the causation of lower genital tract neoplasia particularly of the cervix and the role played by the human papilloma virus (HPV). Some of the original fundamental clinical studies in relation to HPV were undertaken in this unit. Other studies have investigated the physiological mechanisms within the cervix as they pertain to the causation of cervical neoplasia. At present detailed studies examining the role of molecular markers in the natural history with Professor Doobar and his colleagues and clinical diagnosis of HPV are in progress. Other studies were investigating physical methods for the diagnosis of cervical pre-cancer and cancer using the Truscreen device. Studies using x-ray diffraction of hair and other cutaneous tissues in the diagnosis of breast and other cancers are also being undertaken.
He has just completed a series of lectures that have been specifically developed for on line e – learning course in colposcopy and lower genital tract precancer management. The ten hour course has been approved by leading societies in the UK and Europe (colposcopycourses.com)
Teaching Role
Has always maintained an active interest especially in postgraduate gynaecological teaching, particularly in relation to colposcopy. For thirty two years he has run 112 basic and advanced courses teaching colposcopy courses at the Whittington Hospital, and University College London attracting students worldwide. Between 2001-2007 he undertook 11 teaching programme of colposcopy and cervical screening three times a year, in China. He regularly runs courses in many countries. He has produced a series of teaching textbooks and atlases as listed below.
Management/Administrative Role
On an international level is a founding member and board member of the EUROGIN (European Research Society for Gynaecological Infection and Neoplasia). He was President of the 8th EUROGIN Congress in Paris in April 2006. Past President of the British Society of Colposcopy and Cervical Pathology, as well as a Board member of many other societies. He is a member of the Editorial Board of a number of major international and national journals.
2002 -2010 was the Lead Clinician in the QA (Quality Assurance) for Colposcopy in respect of the NHS Cervical Screening Programme.
Professor Singer has been the recipient of numerous national and International awards over many years. He has chaired many international and NHS committees.
Co-founder of the British Society for Colposcopy and Cervical Pathology (1972) and co-founder of British Gynaecological Cancer Group (1978) the forerunner of the British Society for Gynaecological Oncology. Publications. Over three hundred individual and co-authored publications have been produced as well as textbooks as listed above.
JOSEPH JORDAN, DL, MD; FRCOG; FRCPI (Hon)
Qualified University of Durham 1960
In 1966 appointed British Empire Campaign Research Fellow, University of Birmingham, England.
In 1967 visited the Norwegian Radium Hospital to study colposcopy under the supervision of Prof. Per Kolstad,
following which I returned to England to establish a Colposcopy clinic. This transformed the management of
 cervical premalignant disease in the UK. Teaching courses were organised and in 1972, with Prof Albert Singer,
the British Colposcopy Group, later to become the British Society for Colposcopy and Cervical Pathology, was
formed.

In 1968 the surface ultrastructure of premalignant and malignant cells was described.

In 1978 the use of the CO2 Laser for the treatment of CIN was introduced.

Honorary Positions
1976-79       President British Society for Colposcopy and Cervical Pathology
1978-81       President international Federation for Cervical Pathology and Cervical Pathology
1978-81       President Pan American Cancer Cytology Society
1980-86       Vice President Gynaecological Laser Society
1991-93       President Section of Obstetrics and Gynaecology Royal Society of Medicine
1995-2004   President European Federation for Colposcopy

Interests outside medicine
Rugby Union – since 1972 I have been closely involved with Birmingham’s main Rugby Club, as Medical
Officer, President and now Trustee.

Church – I have been a Churchwarden for many years.

Birmingham Civic Society – an organisation which represents the views of the citizens of Birmingham to
Birmingham City Council.

Opera

Golf
Professor Helga Salvesen, MD, PhD
University of Bergen, Haukeland University Hospital, Bergen, Norway

Born in Oslo, Norway in 1963.

Education, training and academic appointments:
MD, Un. of Bergen, Norway (1989); PhD Un. of Bergen (cancer research) (2000); Visiting scholar, Un.of Chicago, USA (1998-99); Specialist in obstetrics and gynecology, Norway (EBCOG requirements) (2001); Consultant in gynecologic oncology, Haukeland Un. Hospital, Norway (2001); Professor, Un. of Bergen (2003); Visiting professor, Harvard University, Dana Farber Cancer Institute, Boston, USA (2004-05); Visiting professor, Harvard University, Broad Institute, USA (2012-13).

Scientific experience: HI 25, ≈115 PubMed listed original articles. Population based tissue bank for gynecologic malignancies, Un. of Bergen (PI); International prospective multicenter trial MoMaTEC (Molecular Markers in Treatment of Endometrial Cancer (PI).

Trainees: 5 (past) and 8 (current) PhD students; 7 postdocs; 3 medical students.

Invited speaker: Harvard/DFCI (2006, 2009); Max Planck Institute, Cologne, Germany (2009); 13th Biennial Meeting International Gynecologic Cancer Society (IGCS), Prague (2010); 17th Meeting of European Society of Gynaecological Oncology (ESGO), Milan (2011); American Society of Clinical Oncology (ASCO) meeting, Chicago (2011); European Society for Medical Oncology (ESMO) meeting, Stockholm (2011).

Prizes/awards: Best presentation at the Annual meeting of Norwegian Gynecological society (1996); twice appointed best teacher, medical school (preclinical), Un. of Bergen (1997,98); Superscientists, Federation of Scandinavian Societies of Obstetrics and Gynecology (1998); Falchs juniorprice, Un. of Bergen (2003); Fulbright Foundation award for overseas studies, Harvard, Boston, USA (2004); Publication of the year, Medical Faculty, Un. of Bergen for PNAS paper (2009); Helse Vest Inovation prize (2011).

Major administrative experiences: President, Norwegian Forum for Gynecologic Oncology (2003-10); President, Norwegian Oncologic Forum (2007-08); Board member (secretary), Chairman surgery group, Nordic Society for Gynecologic Oncology (2006-10); Assistant Dean, Department of Clinical Medicine, Un. of Bergen (2005-10); Board member FriMed Norwegian Research Council (2005-09); Senior editor, International Journal of Gynecological Cancer (2008-); Council member, European Society for Gynecologic Oncology (ESGO) (2009-); Member of the Uterine task Force NCI/NIH (2010-); Disease working group, The Cancer Genome Atlas (TCGA) for Endometrial Cancer (2010-); Chair, European Network for Individualized Treatment of Endometrial Cancer (ENITEC) (2010-); Member of steering group, European Network for Translational Research in Gynecologic Oncology (ENTRIGO) (2010-).

Patents/Licensing agreement: US 12/962,946, covered by license agreement with OvaGene.
Dr. Bjørn Bussund  
Oslo University Hospital, the Norwegian Radium Hospital, Oslo, Norway

Born 22nd of February 1954

Education

1990  Specialist in Gynaecology and Obstetrics
1983  Medical Exam (University of Oslo)

Positions

2015 -  Acting Head of Women- and Children’s Division, Oslo University Hospital (OUH)
2010 -  Head of Dept. of Gynaecology, OUH
2001 – 2010  Head of Dept. of Gynaecology, Ullevaal University Hospital (UUH), Oslo
1999 – 2001  Consultant, Dept of Gynaecology, UUH, Oslo
1990 – 1999  Consultant, Dept of Gynaecology, Aker University Hospital, Oslo
1986 – 1990  Resident National Hospital, Oslo, different depts
1985 – 1986  Resident, Ob/Gyn, Telemark Hospital, Porsgrunn
1983 – 1984  Internship, Telemark Hospital/Municipality of Vadsø

Publications: 9
Sponsored by

RADlUM HOSPITAL FOUNDATION